Published in Medical Letter on the CDC and FDA, February 2nd, 2003
"Sensitivity was highest for age of <5 years (93%-97%) and residual weakness (74%-96%)," wrote Kathryn A. Kohler and colleagues at the Centers for Disease Control and Prevention in the United States...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.